Novo Nordisk and Eli Lilly report GLP-1 signs of slowed biological aging
Novo Nordisk and Eli Lilly presented findings at ARDD indicating potential signals of slowed biological aging associated with GLP-1 treatments.
Novo Nordisk and Eli Lilly presented findings at ARDD indicating potential signals of slowed biological aging associated with GLP-1 treatments.